Visão geral da empresa
A biotechnology enterprise named Cocrystal Pharma, Inc. is dedicated to the discovery and development of antiviral therapeutic treatments designed to address serious and chronic viral diseases within the United States market. The company leverages structure-based technologies to formulate antiviral drugs specifically targeting pathogens such as the influenza virus and coronaviruses, aiming to fill critical gaps in current antiviral therapy options. Operating within the healthcare sector and the biotechnology industry, the firm functions as a specialized developer of medical products rather than a diversified healthcare conglomerate. With a market capitalization of $19.71M and an employee base of 10, the company maintains a very small operational scale typical of early-stage biotechnology firms. These valuation figures indicate that the market prices the entity as a micro-cap asset, suggesting high volatility and significant potential for expansion but also exposing it to substantial risk compared to larger, established pharmaceutical peers. The minimal workforce of 10 employees further underscores the lean, resource-constrained nature of the organization, where a small team bears the responsibility of advancing complex drug discovery programs from concept to clinical development.
Saúde financeira
Cocrystal Pharma, Inc. reports a Net Income (TTM) of $-8,831,000 and an EBITDA of $-8,947,000, while its annual revenue figures are listed as N/A in current reporting periods. The absence of reported revenue combined with substantial negative net income reveals a cost structure dominated by research and development expenditures, clinical trial costs, and general administrative overhead that far exceed any current sales generated. The company generates a Free Cash Flow of $-4,946,875, which indicates that the firm is burning cash rapidly to fund its operations and drug development initiatives. This negative cash flow position implies limited financial flexibility in the short term, requiring the company to rely on external capital raises, grants, or existing cash reserves to sustain its business model. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a figure that reflects the company's current inability to generate revenue or operate profitably while it remains in the development phase. Regarding liquidity and leverage, the company holds $7.03M in cash against $1.50M in debt, resulting in a Debt to Equity ratio of 23.77, which suggests a balance sheet that is currently un-leveraged in terms of absolute debt burden despite the negative equity implied by losses. The Current Ratio stands at 3.68, indicating a robust short-term liquidity position where current assets significantly exceed current liabilities, providing a comfortable buffer for meeting immediate obligations. Return on Equity is reported at -111.4% and Return on Assets at -48.7%, metrics that reveal management has yet to achieve profitability and that the company is currently destroying shareholder value through its investment in unproven assets rather than generating returns.
Avaliação de valorização
The valuation metrics for Cocrystal Pharma, Inc. present a mixed picture, with a P/E Ratio (TTM) listed as N/A due to the lack of earnings and a Forward P/E of -1.47. The negative Forward P/E implies that analysts or market models expect earnings to remain negative in the coming year, reflecting the ongoing nature of the company's cash burn rather than an anticipated immediate turnaround. The Price to Book ratio is 3.12, which indicates that the stock is trading at a significant premium relative to its tangible book value, a common characteristic for biotechnology companies where future pipeline value is often priced in despite current asset deficits. Alternative valuation metrics such as Price to Sales (N/A) and EV/EBITDA (-1.59) are also skewed by the lack of positive earnings and sales, suggesting that traditional valuation multiples are not applicable for this stage of development. The stock's price range over the last year has fluctuated between a 52-Week High of $2.67 and a 52-Week Low of $0.86, meaning the current price sits at a point that reflects the market's ongoing uncertainty regarding the company's clinical prospects. The Beta value of 1.18 indicates that the stock is 18% more volatile than the broader market, exposing investors to higher swings in price that correlate with the high-risk profile of small-cap biotechnology stocks.
Growth & Income
Cocrystal Pharma, Inc. reports a Revenue Growth (YoY) of N/A and an Earnings Growth (YoY) of N/A, as the company has not yet generated consistent commercial revenue to calculate year-over-year expansion rates. The inability to calculate growth rates implies that the company is in a pre-commercialization stage where the focus is entirely on product development rather than scaling sales or expanding earnings. Regarding income generation, the company does not pay a dividend, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%. Since the company is not a dividend payer, it does not distribute cash to shareholders, instead choosing to reinvest its limited capital entirely into research, development, and clinical trials to advance its antiviral drug pipeline. Consequently, the overall growth and income profile for Cocrystal Pharma is defined by capital expenditure and asset accumulation rather than cash flow generation or shareholder yield, representing a classic high-risk, high-reward investment thesis dependent on successful clinical outcomes.